DE69813200D1 - Verbesserung der wundheilung mit cm101/gbs-toxin - Google Patents

Verbesserung der wundheilung mit cm101/gbs-toxin

Info

Publication number
DE69813200D1
DE69813200D1 DE69813200T DE69813200T DE69813200D1 DE 69813200 D1 DE69813200 D1 DE 69813200D1 DE 69813200 T DE69813200 T DE 69813200T DE 69813200 T DE69813200 T DE 69813200T DE 69813200 D1 DE69813200 D1 DE 69813200D1
Authority
DE
Germany
Prior art keywords
gbs
toxin
wounds healing
improving wounds
improving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69813200T
Other languages
English (en)
Other versions
DE69813200T2 (de
Inventor
G Hellerqvist
Michal Neeman
D Wamil
Rinat Abramovitch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Vanderbilt University
Original Assignee
Yeda Research and Development Co Ltd
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Vanderbilt University filed Critical Yeda Research and Development Co Ltd
Publication of DE69813200D1 publication Critical patent/DE69813200D1/de
Application granted granted Critical
Publication of DE69813200T2 publication Critical patent/DE69813200T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69813200T 1997-01-29 1998-01-29 Verbesserung der wundheilung mit cm101/gbs-toxin Expired - Fee Related DE69813200T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US791763 1997-01-29
US08/791,763 US5858991A (en) 1997-01-29 1997-01-29 Facilitation of wound healing with CM101/GBS toxin
PCT/US1998/001853 WO1998032453A1 (en) 1997-01-29 1998-01-29 Facilitation of wound healing with cm101/gbs toxin

Publications (2)

Publication Number Publication Date
DE69813200D1 true DE69813200D1 (de) 2003-05-15
DE69813200T2 DE69813200T2 (de) 2004-02-12

Family

ID=25154717

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69813200T Expired - Fee Related DE69813200T2 (de) 1997-01-29 1998-01-29 Verbesserung der wundheilung mit cm101/gbs-toxin

Country Status (13)

Country Link
US (3) US5858991A (de)
EP (1) EP0973531B1 (de)
JP (1) JP2001509169A (de)
CN (1) CN100389776C (de)
AT (1) ATE236647T1 (de)
AU (1) AU6051898A (de)
DE (1) DE69813200T2 (de)
DK (1) DK0973531T3 (de)
ES (1) ES2196539T3 (de)
HK (1) HK1027755A1 (de)
IL (1) IL131001A0 (de)
PT (1) PT973531E (de)
WO (1) WO1998032453A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US5981508A (en) * 1997-01-29 1999-11-09 Vanderbilt University Facilitation of repair of neural injury with CM101/GBS toxin
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US6803448B1 (en) 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
EE200100372A (et) 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
ATE465751T1 (de) * 2000-02-02 2010-05-15 Univ Vanderbilt Verfahren zur vorbeugung und linderung angiogener erkrankungen durch impfung mit dem rezeptor für gbs-toxin (cm101)
JP2004500844A (ja) * 2000-05-08 2004-01-15 バイオジェン　インコーポレイテッド Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
AU2003224950B2 (en) 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
US8017145B2 (en) * 2003-12-22 2011-09-13 Conopco, Inc. Exfoliating personal care wipe article containing an array of projections
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US8877185B2 (en) 2012-05-10 2014-11-04 Stan S. Sastry Managing and treating keloids

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS557014A (en) * 1978-06-29 1980-01-18 Chugai Pharmaceut Co Ltd Antitumor agent and its preparation
US5145676A (en) * 1981-09-08 1992-09-08 The Rockefeller University Method and agents for promoting wound healing
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4912093A (en) * 1986-10-01 1990-03-27 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
US4895838A (en) * 1988-03-09 1990-01-23 Trustees Of Boston University Method for provoking angiogenesis by administration of angiogenically active oligosaccharides
US5010062A (en) * 1989-09-25 1991-04-23 Vanderbilt University Therapeutic agent and method of inhibiting vascularization of tumors
US5225331A (en) * 1991-04-25 1993-07-06 National Research Council Of Canada Immunoassay for detecting group b streptococcus
US5160483A (en) * 1991-05-07 1992-11-03 The University Of Tennessee Research Corporation Fragment of TNF-α for promoting wound healing
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
DK0666868T4 (da) * 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
EP0809511A1 (de) * 1995-02-16 1997-12-03 F. Hoffmann-La Roche Ag Hemmung der angiogenese mittels interleukin-12
AU2438297A (en) * 1996-05-09 1997-11-26 Alcon Laboratories, Inc. Combinations of angiostatic compounds
US5811403A (en) * 1996-09-30 1998-09-22 Vanderbilt University Polysaccharide toxin from Group B β-hemolytic Streptococcus (GBS) having improved purity

Also Published As

Publication number Publication date
DE69813200T2 (de) 2004-02-12
DK0973531T3 (da) 2003-07-28
WO1998032453A1 (en) 1998-07-30
CN100389776C (zh) 2008-05-28
US20030180331A1 (en) 2003-09-25
ES2196539T3 (es) 2003-12-16
US5858991A (en) 1999-01-12
AU6051898A (en) 1998-08-18
US6569838B1 (en) 2003-05-27
ATE236647T1 (de) 2003-04-15
HK1027755A1 (en) 2001-01-23
PT973531E (pt) 2003-08-29
EP0973531A1 (de) 2000-01-26
IL131001A0 (en) 2001-01-28
JP2001509169A (ja) 2001-07-10
CN1251998A (zh) 2000-05-03
EP0973531B1 (de) 2003-04-09

Similar Documents

Publication Publication Date Title
AP1401A (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic- depressive bipolar disorder.
DE69813200D1 (de) Verbesserung der wundheilung mit cm101/gbs-toxin
CA2424242A1 (en) Methods for treating muscle injuries
BG100960A (en) Dosage forms for controlled release of azitromycin
GB9516287D0 (en) Pharmaceutical compositon
EP0869801A4 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
GB9521608D0 (en) Pharmaceutical composition
DE69717988D1 (de) Topische verabreichung von premafloxacin zur behandlung von systemischen bakteriellen erkrankungen
DK0445280T3 (da) Terapeutisk middel og fremgangsmåde til inhibering af vaskularisering af tumorer
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
AU1278600A (en) Novel therapeutic application of nicergoline
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
NO984198L (no) FremgangsmÕte for behandling av aggresjon
NO984190L (no) FremgangsmÕte for behandling av insomnia
ATE184487T1 (de) Transdermales therapeutisches system für silatranverbindungen
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
PT1313500E (pt) Associacoes de dalfopristina/quinupristina com o cefpirome
UA30556A (uk) Спосіб модуляції гоєння ран
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee